At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 52 target
Drug / intervention
BL-B01D1 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06405425Phase 2RecruitingMonitorUpdated 13mo ago · Completion was 2mo agoSlow Enrollment
Monitor
A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 + PD-1 Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
In Brief
A Phase 2 clinical trial evaluating BL-B01D1 and PD-1 for Urothelial Carcinoma. Currently recruiting, targeting 52 participants across 1 site.
Signals
Enrolling slower than its timeline implies
Detailed Summary
This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 combination therapy in patients with locally advanced or metastatic urothelial carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrothelial Carcinoma
CountriesChina
CollaboratorsBaili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Timeline
Phase 2RecruitingOverdue
20252026
First PostedMay 2024
Enrollment StartMay 2024
Primary CompletionMay 2026
TodayJul 2026
First PostedMay 8, 2024
Enrollment StartMay 29, 2024
Primary CompletionMay 1, 2026
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 2.1 years ago
Interventions
BL-B01D1drug
Administration by intravenous infusion for a cycle of 3 weeks.
PD-1drug
Administration by intravenous infusion for a cycle of 3 weeks.